News

Anil Singhvi Buy/Sell Call: The mid-week session began with a clear strategy from market expert Anil Singhvi, who laid out his trading roadmap for investors. His latest recommendations mix selective buying in fundamentally sound counters and caution in underperformers after the Q2 results season. Singhvi’s call this time leans on earnings quality and operational resilience, two factors he believes will matter most as the market moves into the festive quarter.

IOL Chemicals is among Singhvi’s top picks for the day. The analyst expects near-term upside following an improvement in margins and overall operational stability. He suggests a stop loss at Rs 87, with upside targets of Rs 91, Rs 93 and Rs 95. “The results have been excellent across parameters, showing the company’s strong footing,” Singhvi noted.

BSE has delivered another impressive quarter, prompting Singhvi to maintain a positive stance. He recommends a buy on BSE Futures with stop loss at Rs 2,605 and targets at Rs 2,675, Rs 2,695 and Rs 2,720. The stock has already gained about 11 per cent over the past month, yet Singhvi sees scope for further momentum.

The next pick on Singhvi’s buy list is Fortis Healthcare, which posted results stronger than market expectations. He suggests a buy on Fortis Health Futures with stop loss at Rs 963 and targets of Rs 1,010 and Rs 1,025. Despite a 7 per cent slide in the last month, Singhvi believes the company’s consistent earnings will support a rebound.

On the other hand, Singhvi has advised investors to avoid RVNL Futures, as the company’s quarterly performance remained soft. He set a stop loss at Rs 322 with targets at Rs 310, Rs 304 and Rs 295. He also flagged Biocon, CONCOR, and Tata Power for showing mixed or weak trends. For Biocon, support lies near Rs 373 with resistance at Rs 400; CONCOR’s support is seen around Rs 511 and resistance near Rs 538; while Tata Power may face selling pressure between Rs 383–Rs 409.

Singhvi said traders should stay selective and focus on companies delivering steady results. “In this phase, earnings and execution strength are more important than momentum alone,” he added. With the Q2 season nearing its close, Singhvi’s approach remains data-driven — buy strength, avoid weakness, and ride quality stocks through volatility.

Senior Sub-editor at Zee Business English

shweta.shukla@India.com

Shweta Birendra Shukla is a journalist covering the stock market and corporate aff